CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗间皮素 CAR-T 细胞治疗的挑战
英文原题：Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
查看英文原题
Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法是近年来快速发展的过继性 T 细胞疗法（ACT）。间皮素（MSLN）是一种肿瘤相关抗原（TAA），在多种实体瘤中高表达，是开发实体瘤新型免疫疗法的重要靶抗原。本文综述抗 MSLN CAR-T 细胞疗法的临床研究现状、障碍、进展和挑战。抗 MSLN CAR-T 临床试验显示，该疗法安全性较高，但疗效有限。目前采用局部给药和引入新型修饰，以增强抗 MSLN CAR-T 的增殖和持续存在能力，并改善疗效与安全性。多项临床和基础研究显示，该疗法与标准治疗联用的疗效显著优于单药治疗。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T-cell therapy is a kind of adoptive T-cell therapy (ACT) that has developed rapidly in recent years. Mesothelin (MSLN) is a tumor-associated antigen (TAA) that is highly expressed in various solid tumors and is an important target antigen for the development of new immunotherapies for solid tumors. This article reviews the clinical research status, obstacles, advancements and challenges of anti-MSLN CAR-T-cell therapy.
Clinical trials on anti-MSLN CAR-T cells show that they have a high safety profile but limited efficacy. At present, local administration and introduction of new modifications are being used to enhance proliferation and persistence and to improve the efficacy and safety of anti-MSLN CAR-T cells. A number of clinical and basic studies have shown that the curative effect of combining this therapy with standard therapy is significantly better than that of monotherapy.
论文信息
- 作者
- Zhai X、Mao L、Wu M、Liu J、Yu S
- 单位
- Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.China
- 文献类型
- 综述
- 期刊
- Cancers2023 Feb 21
- 原文标识
- PubMed 36900151 · DOI 10.3390/cancers15051357
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →